Anavex Life Sciences Reports Fiscal 2025 Q4 Net Loss of $9.8M and CHMP Negative Vote for Blarcamesine

ANAVEX LIFE SCIENCES CORP.

2025-FY EPS reported -$0.54

Net loss for Q4 fiscal 2025 was $9.8M ($0.11 per share), compared to net loss of $11.6M ($0.14) in Q4 fiscal 2024.
Cash and cash equivalents were $102.6M at September 30, 2025, down from $132.2M a year ago; current cash over $120M with >3 year runway.
CHMP of EMA issued a negative trend vote on the Marketing Authorisation Application for blarcamesine; Anavex intends to request re-examination.
Positive topline results from Phase 2 study of ANAVEX3-71 for schizophrenia: safe and well-tolerated, primary safety endpoint met.
Research & development expenses for the quarter were $7.3M, down from $11.6M in the prior year quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.